股票 › DMII
美国制药收购公司二号 DMII
美股市值排名 #3522
$10.21 −$0.01 (-0.10%)
休市 · Nov 6, 8:10 pm ET
开盘$10.21
昨收$10.22
当日区间$10.21 – $10.21
成交量70.1K
市值$650.38M
市盈率（TTM）35.0
股息率–
股权结构与仓位
谁在持有、谁在做空，以及大资金的流向
机构持股比例77.0%+0.03 个百分点，较上季度
持仓机构数75+0 ，较上季度
内部人近期交易6次买入 / 2次卖出净买入
空头持仓比例0.17% 占流通股回补天数 1.0 · 截至 15 Oct 2026
卖空成交量占比0.7%近5日成交量平均占比
卖空成交量占当日成交量比例
大单净流入，近20个交易日
大单买入减卖出的净额（美元）。该窗口期内：−$33.62M（1个净流入日，19个净流出日）。
按单量净流入，近20个交易日
超大单/大单近似机构级别交易；中单/小单近似散户级别交易。各档买入减卖出净额，按窗口期累计。
已披露的前五大股东合计持有21.2%的流通股。
最大股东
按投资者类型
过去6次双周报告中（31 Jul 2026至15 Oct 2026），空头持仓占流通股比例已基本持稳于0.17%。
近期机构持仓变动
| 股东 | 类型 | 期间 | 持股变动 | 新持股比例 |
|---|---|---|---|---|
| Principal Global Investors, LLC | Mutual Fund | 2026/Q3 | +10,374 | 0.0% |
| FMR | Mutual Fund | 2026/Q3 | +6,268 | 0.1% |
| Highbridge Capital Management, LLC | Hedge Fund | 2026/Q3 | +2,016,211 | 3.5% |
| CrossingBridge Advisors, LLC | Mutual Fund | 2026/Q3 | +750,000 | 1.7% |
| TIG Advisors, LLC | Hedge Fund | 2026/Q3 | +500,000 | 0.8% |
| JPMorgan Chase & Co. | Public Company | 2026/Q3 | +426,321 | 0.9% |
| Logan Stone Capital, LLC | Hedge Fund | 2026/Q3 | +370,373 | 0.6% |
| Cantor Fitzgerald Asset Management | Mutual Fund | 2026/Q3 | +363,100 | 0.6% |
| Kepos Capital LP | Hedge Fund | 2026/Q3 | +210,000 | 0.3% |
| Clear Street LLC | Private Company | 2026/Q3 | +209,534 | 0.4% |
| Karpus Management Inc. | Mutual Fund | 2026/Q3 | +190,075 | 4.4% |
| Limestone Investment Advisors LP | Mutual Fund | 2026/Q3 | +139,100 | 0.2% |
| Westchester Capital Management, LLC | Mutual Fund | 2026/Q3 | +121,791 | 1.0% |
| D. E. Shaw & Co., L.P. | Hedge Fund | 2026/Q3 | +84,900 | 2.3% |
| Arax Advisory Partners, LLC | Mutual Fund | 2026/Q3 | +65,990 | 0.1% |
按报告期列出的机构买卖动态，变动幅度从大到小排列。
内部人交易
| 日期 | 内部人 | 职位 | 交易类型 | 股数 | 价格 | 交易后持股 |
|---|---|---|---|---|---|---|
| 25 Sep 2025 | Glenn Worman | Former Chief Financial Officer | Other Acquisition | +100,000 | – | 100,000 |
| 25 Sep 2025 | Sridhar Prasad | Independent Director | Other Acquisition | +100,000 | – | 100,000 |
| 25 Sep 2025 | Catherine Do | Independent Director | Other Acquisition | +100,000 | – | 100,000 |
| 25 Sep 2025 | Myron Shulgan | Independent Director | Other Acquisition | +100,000 | – | 100,000 |
| 25 Sep 2025 | Drugs Made In America Acquisition II LLC | Other Disposition | -400,000 | – | 6,708,333 | |
| 25 Sep 2025 | Drugs Made In America Acquisition II LLC | Private Acquisition | +700,000 | – | 6,708,333 | |
| 25 Sep 2025 | Drugs Made In America Acquisition II LLC | Private Disposition | -7,966,667 | – | 6,708,333 | |
| 25 Sep 2025 | Drugs Made In America Acquisition II LLC | Open Market Derivative Acquisiti | +700,000 | – | 700,000 | |
| 23 Sep 2025 | Drugs Made In America Acquisition II LLC | Initial Statement of Beneficial | +0 | – | 14,375,000 |
数据来自Form 4/Form 144申报文件。负数为减持（出售、赠予或代扣税款股份），正数为增持。
空头持仓（按报告期）
| 报告日期 | 空头股数 | 占流通股比例 | 回补天数 |
|---|---|---|---|
| 15 Oct 2026 | 111,243 | 0.2% | 1.0 |
| 30 Sep 2026 | 121,549 | 0.2% | 2.1 |
| 15 Sep 2026 | 126,137 | 0.2% | 3.3 |
| 31 Aug 2026 | 119,323 | 0.2% | 1.9 |
| 14 Aug 2026 | 121,957 | 0.2% | 159.6 |
| 31 Jul 2026 | 135,284 | 0.2% | 1.4 |
暂无评论——快来第一个聊聊 DMII。
登录后参与讨论。